Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20180680 | 1.00 | HTT (0.34) | HTTGPBAR1ALDH1A1FKBP1ABACE1 | |
| SCHEMBL23369279 | 1.00 | HTT (0.34) | HTTGPBAR1ALDH1A1FKBP1ABACE1 | |
| SCHEMBL12013341 | 1.00 | HTT (0.34) | HTTGPBAR1ALDH1A1FKBP1ABACE1 | |
| SCHEMBL20180516 | 1.00 | HTT (0.34) | HTTGPBAR1ALDH1A1FKBP1ABACE1 | |
| SCHEMBL19533069 | 1.00 | HTT (0.34) | HTTGPBAR1ALDH1A1FKBP1ABACE1 | |
| SCHEMBL26755735 | 0.87 | ACHE (0.32) | ALDH1A1FKBP1A | |
| SCHEMBL19245754 | 0.86 | GPBAR1 (0.31) | GPBAR1ALDH1A1BACE1BACE2 | |
| SCHEMBL21126773 | 0.86 | GPBAR1 (0.31) | GPBAR1ALDH1A1BACE1BACE2 | |
| SCHEMBL17570992 | 0.86 | ALDH1A1 (0.33) | GPBAR1ALDH1A1BACE1BACE2 | |
| SCHEMBL24952144 | 0.86 | GPBAR1 (0.31) | GPBAR1ALDH1A1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381330-A1 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230381330-A1 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| WO-2022087243-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| WO-2020132483-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2018093866-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381330-A1 | ENZYME-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | DNPEP, ENGASE, ENPEP | HTT 3730/4885GPBAR1 3179/4885ALDH1A1 385/4885 |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ERBB3, HDAC6, ERBB2 | HTT 685/4885GPBAR1 2156/4885ALDH1A1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.